Propanc Biopharma, Inc. — Form 10-Q Summary
Period: The filing covers the quarter and nine months ended March 31, 2018; it was signed May 10, 2018. This is the company’s fiscal third quarter of 2018, despite the request metadata identifying 2017 Q3. Financial statements are unaudited.
Business context
Propanc is a pre-revenue biotechnology company developing PRP, a pro-enzyme cancer treatment candidate. PRP remained in preclinical development; the company reported no products available for sale and no clinical trials underway. It was preparing manufacturing work and a UK clinical trial application.
Financial performance and position
| Metric | Three months ended March 31 | Nine months ended March 31 |
|---|---|---|
| Revenue | $0 in 2018 and 2017 | $0 in 2018 and 2017 |
| Operating expenses | $807,135 in 2018; $1,547,277 in 2017 | $3,448,180 in 2018; $4,630,660 in 2017 |
| Net loss | $1,491,006 in 2018; $1,371,126 in 2017 | $5,616,728 in 2018; $6,234,008 in 2017 |
| Operating cash used | Not presented for the quarter | $1,730,085 in 2018; $1,449,080 in 2017 |
- Nine-month R&D expense rose to $1,673,606 from $714,889, while administration expense fell to $1,750,840 from $3,893,534. For the quarter, R&D declined to $75,138 from $386,490.
- At March 31, cash was $9,296, total assets $110,746, current liabilities $6,883,660, and stockholders’ deficit $6,772,914. The filing reports a $6,784,373 working-capital deficit and accumulated deficit of $43,860,251.
- Balance-sheet convertible notes and related accrued interest, net of discounts and premiums, were $4,514,921. The notes separately report $3,128,435 of convertible-note principal/debenture, before related discounts, accrued interest and premiums. MD&A also describes total debt outstanding as $3,128,435.
- Financing provided $1,893,255 of cash in the nine months, including $2,385,781 of convertible-note proceeds offset by $490,181 of note repayments. Cash declined by $59,747, including a $222,917 adverse foreign-exchange effect.
- Basic and diluted loss per share was $0.06 for the quarter and $0.42 for the nine months in 2018. Weighted-average shares were 23,426,370 and 13,247,004, respectively. The filing reports 31,060,132 common shares outstanding at March 31 and 38,324,191 at May 10.
Changes, outlook, and material risks
- Nine-month net loss improved year over year, mainly as lower administration costs more than offset higher R&D spending. Quarterly net loss worsened, partly because the tax benefit fell to $485 from $306,159 and foreign-currency and derivative items changed.
- Management stated that available cash was insufficient for the next 12 months and that substantial doubt existed about the company’s ability to continue as a going concern. Additional financing was considered necessary; management said it might reduce R&D spending or consider licensing, joint ventures, or mergers if funding proved insufficient.
- At March 31, the company was in default on Eagle Equities notes with an aggregate $769,933 of principal and accrued interest, and was discussing maturity extensions. Other notes had also matured; several financing agreements carry default rates of up to 24%, variable-price conversion terms, and potential penalties.
- Convertible debt created substantial potential dilution. The filing identified 57,448,803 shares issuable upon conversion of notes, 98,727,377 shares reserved for future lender issuances, and 149,517 warrants outstanding. Common shares authorized had been increased to 400 million.
- After quarter-end, conversions from April 2–30 resulted in additional shares being issued, and the company entered into April financing with GS Capital for notes totaling $300,000 in principal. The filing describes further discount-to-market conversion provisions.
- Development milestones included completion of a 28-day toxicity study without treatment-related findings, reported process development for the active substances, and a March 2018 scientific-advice meeting with the UK MHRA. A UK first-in-human study remained a future objective, not an achieved milestone. PRP had FDA orphan-drug designation for pancreatic cancer; a request for ovarian cancer designation was denied.
- Management reported ineffective disclosure controls and an ongoing material weakness involving limited accounting expertise for complex debt and equity transactions and inadequate segregation of duties. The filing also disclosed a $30,000 IRS penalty plus interest for late informational filings and ongoing manufacturing commitments to Amatsigroup; expected payments under that agreement were $2.5 million–$5.0 million over five years.
Important facts for investors to verify
- Reconcile the reported debt amounts across principal, accrued interest, discounts, put premiums, and balance-sheet carrying value; confirm current status of matured and defaulted notes and any extensions.
- Assess near-term liquidity and financing availability, including post-quarter financing proceeds, conversion activity, and the cash runway.
- Quantify potential dilution from variable-price conversion terms, outstanding reserves, subsequent share issuances, and the increased authorized share count.
- Track the timing, funding, and regulatory requirements for GMP manufacturing and any UK clinical trial application; preclinical progress does not establish clinical safety or efficacy.
- Review remediation of the disclosed control weaknesses and any subsequent developments affecting the going-concern assessment.